189 related articles for article (PubMed ID: 36775731)
1. Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
Rujkorakarn P; Patamatamkul S
J Fr Ophtalmol; 2023 Mar; 46(3):207-210. PubMed ID: 36775731
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
3. Bilateral Panuveitis Mimicking Vogt-Koyanagi-Harada Disease following the First Dose of ChAdOx1 nCoV-19 Vaccine.
Kim SY; Kang MS; Kwon HJ
Ocul Immunol Inflamm; 2022 Jul; 30(5):1218-1221. PubMed ID: 35113750
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
5. Possible Association between Vogt-Koyanagi-Harada Disease and Coronavirus Disease Vaccine: A Report of Four Cases.
de Queiroz Tavares Ferreira F; Araújo DC; de Albuquerque LM; Bianchini PM; Holanda EC; Pugliesi A
Ocul Immunol Inflamm; 2023 Aug; 31(6):1134-1140. PubMed ID: 35914285
[TBL] [Abstract][Full Text] [Related]
6. Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine.
Koong LR; Chee WK; Toh ZH; Ng XL; Agrawal R; Ho SL
Ocul Immunol Inflamm; 2021 Aug; 29(6):1212-1215. PubMed ID: 34505819
[TBL] [Abstract][Full Text] [Related]
7.
Brunet de Courssou JB; Tisseyre M; Hadjadj J; Chouchana L; Broca F; Terrier B; Duraffour P; Henriquez S
Ocul Immunol Inflamm; 2022 Jul; 30(5):1292-1295. PubMed ID: 35113742
[TBL] [Abstract][Full Text] [Related]
8. A COVID-19 perspective of Vogt-Koyanagi-Harada disease.
Dutta Majumder P; Sadhu S; González-López JJ; Mochizuki M
Indian J Ophthalmol; 2023 Jun; 71(6):2587-2591. PubMed ID: 37322685
[TBL] [Abstract][Full Text] [Related]
9. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
[TBL] [Abstract][Full Text] [Related]
10. Case report: Bilateral panuveitis resembling Vogt-Koyanagi-Harada disease after second dose of BNT162b2 mRNA COVID-19 vaccine.
Sato T; Nihei R; Sora D; Nishio Y; Takeuchi M
Front Immunol; 2022; 13():967972. PubMed ID: 36248859
[TBL] [Abstract][Full Text] [Related]
11. Harada-like syndrome post-Covishield vaccination: A rare adverse effect.
Reddy Y; Pandey A; Ojha A; Ramchandani S
Indian J Ophthalmol; 2022 Jan; 70(1):321-323. PubMed ID: 34937269
[TBL] [Abstract][Full Text] [Related]
12. Vogt-Koyanagi-Harada disease during prolonged intermittent steroid therapy for chronic obstructive pulmonary disease: a case report.
Akulwar S; Gupta H; Pustake M; Vidhale T; Lahane S; Rohan PJ
Pan Afr Med J; 2021; 39():101. PubMed ID: 34512837
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada Disease Associated with Hepatitis B Vaccination.
Sood AB; O'Keefe G; Bui D; Jain N
Ocul Immunol Inflamm; 2019; 27(4):524-527. PubMed ID: 29953303
[No Abstract] [Full Text] [Related]
15. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database.
Keh RYS; Scanlon S; Datta-Nemdharry P; Donegan K; Cavanagh S; Foster M; Skelland D; Palmer J; Machado PM; Keddie S; Carr AS; Lunn MP;
Brain; 2023 Feb; 146(2):739-748. PubMed ID: 35180300
[TBL] [Abstract][Full Text] [Related]
18. Vogt-koyanagi-harada syndrome.
Fang W; Yang P
Curr Eye Res; 2008 Jul; 33(7):517-23. PubMed ID: 18600484
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
